AEs	Adverse events
ALF	Acute liver failure
ART	Antiretroviral therapy
BMI	Body mass index
CHC	Chronic hepatitis C
CI	Confidence interval
CLD	Chronic liver disease
DAAs	Direct-acting antivirals
DNHB	de novo HBV infection
ESLD	End-stage liver disease
HAART	Highly active antiretroviral therapy
HAV	Hepatitis A virus
HAVac	Hepatitis A vaccines
HAV-L	Live-attenuated HAV vaccines
HBBI	Hepatitis B breakthrough infection
HBV	Hepatitis B virus
HBsAg	Hepatitis B surface antigen
HBsAb/anti-HBs	Hepatitis B surface antibody
HbeAg	Hepatitis B e antigen
HBIG	Hepatitis B immunoglobulin
HBVac	Hepatitis B vaccine
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HEV	Hepatitis E virus
HIV	Human immunodeficiency virus
HR	Hazard ratio
IFN-γ	Interferon gamma
IgG	Immunoglobulin G
IL	Interleukin
GM-CSF	Granulocyte–macrophage colony-stimulating factor
GMC	Geometric mean concentration
GMT	Geometric mean titer
LDLT	Living donor liver transplant
LT	Liver transplant
MIP-1α	Macrophage inflammatory protein-1α
NAFLD	Non-alcoholic fatty liver disease
OLT	Orthotopic liver transplant
PLWH	People living with HIV
PMTCT	Prevention of mother-to-child transmission
PVST	Post-vaccination serologic testing
RCT(s)	Randomized controlled trial(s)
TDF	Tenofovir disoproxil fumarate
TNF	Tumor necrosis factor
WHO	World Health Organization